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History
 in 1994 by Breaker and Joyce (3)
 trans esterification reaction (3)
 single stranded DNA could indeed act as a catalyst(3)
Process of DNAzym(3)
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4) ligation 1) DNA 
cleavage
2) RNA 
cleavage
3) 
phosphoryla
tion 
DNAzym
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7 Definition
 DNAzymes are catalytically active DNA molecules(6)
 their capability to cleave RNA molecules (6)
 DNAzymes are single-stranded DNA molecules(6)
Structures
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DNAzyme
consist
two binding 
domains flanking 
central catalytic 
domain
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The latter is composed of 15 deoxynucleotide
 the binding domains are variable(9)
Cleaving the mRNA(10)
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 half life from 70 min to 21 h in human serum (2)
 also remain functionally intact for at least 24–48 h in
human serum(2)
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 DNAzymes represent a particular class of antisense
molecule(4)
 inherent catalytic activity which makes them an
attractive tools(4)
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Main   Applications
 also used as active components for constructing
nanostructures (3)
 important functional nucleic acids for chemical biology
medicine, analytical chemistry and materials science. (3)
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 lead to down-regulation of protein expression(5)
 their use as amplifying labels for the development
of optical or electronic sensors(3)
Main   Applications
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advantages as compared to enzymes 
1. In contrast to enzymes that are thermally unstable(8)
2. impressively stable under ambient and even elevated
temperatures(8)
3. may be prepared by the polymerase chain reaction
(PCR). (8)
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1. drug delivery systems (DDSs)
2. DNAzyme-based biosensors and nanodevices
3. Treatment the cancer”s and diseases
Applications
Applications(11)
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 recognition elements and promising signal amplifiers in biosensor (3)
 based on colorimetry, Surface Enhanced Raman Scattering(SERS),
fluorescence, or electrochemistry. (3)
 Broad range of cofactors: such as Pb2+,UO2+, Cu2+, Zn2+, and histidine (3)
DNAzyme-based biosensors and  nanodevices
Different  Cofactors(1)
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Mn2+ 
Mg2+
To investigate whether the produced Mn2+ ions from the reduction of MnO2 nanosheets could act as cofactors
for 10–23 DNAzyme, the effect of Mn2+ on the catalytic activity of DNAzyme for RNA cleavage was analyzed by
agar electrophoresis. It can be seen in Figure 1 that 0.2 mm of Mn2+ ions could trigger 10–23 DNAzyme to
completelycleave the substrate within 60 min. However, under the same conditions, a concentration of 15 mm
was necessary for Mg2+ ions, indicating that the Mn2+ ion was the more efficientcofactor.
Biosensors
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recognition 
element 
transducer  
component 
two basic 
components
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 nanomaterial assisted like AuNPs, GO, CNT, QDs(9)
 provide novel sensing systems based on colorimetry,
dynamic light scattering(DLS), or SERS (9)
Chemiluminescence (CL)(6) 
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Colorimetric (7)
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Treatment the cancer”s and diseases(1)
Activity of DNAzymes against Cancer Cells 
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 inhibited proliferation and induced apoptosis (10)
 induce the release of cytochrome c from
mitochondria(10)
DNAzyme Delivery—Facing the Beast of a Challenge(10) 
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Drug Delivery Systems (DDSs)
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 presenting drug agents against cancer(5)
 target gene knockdown agents(5)
 more emphasis needs to be placed on actual efficacy and safety(5)
 chitosan and polyethylenimine (PEI)(8)
Drug Delivery Systems (DDSs)(3)
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DNAzymes – Short overview of in vitro usage.(5)
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mRNA target                Pathogenesis                                 DNAzyme usage
Bcr-abl Chronic myeloid leukaemia
(CML), acute lymphoblastic
leukaemia (ALL)
Three DNAzymes were designed against two variants of the 
p210 bcr-abl gene and p190 variant. DNAzymes were 
transfected into CML K562 cells using GS2888 cationic 
liposomal reagent.
β 1 and β 3 integrin Important in cell–cell and cell–
matrix
interactions in the pathogenesis of
various tumours.
Two DNAzymes to β 1 and β 3 mRNA were designed to 
contain a
15-deoxynucleotide catalytic domain fl anked by two substrate 
recognition segments of 8 and 10 deoxynucleotides
for β 1 and β 3 DNAzymes, respectively. DNAzymes were 
partially modifi ed with phosphorothioate and with 2’-O-
methyl groups at both the 5’ and 3’ ends.
Epidermal growth
factor receptor 
(EGFR)
Receptor tyrosine kinase of the 
Erb B
receptor family that is abnormally
activated in epithelial tumours.
DNAzymes targeting the EGFR mRNA.
PML/RAR α fusion 
gene
Acute promyelocytic leukaemia
(APL).
DNAzymes (Dz1 and Dz3) were designed to cleave the 
PML/RAR α transcript at the GC nucleotides at the fusion 
point and three nucleotide s upstream of that respectively.
Unique quadruple cleavage activity of designed DNAzymes.
DNAzymes – Short overview of in vivo usage(5)
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mRNA target                Pathogenesis                                 DNAzyme usage
Human survivin in 
PANC-1 cells
Human pancreatic carcinoma –
regulates cell division and 
inhibits apoptosis.
Anti-survivin mRNA DNAzyme designed.
Transfected into PANC-1 cells through liposomes.
Urokinase-type
plasminogen
activator
receptor (uPAR)
Implicated in signal transduction 
and biological processes 
including cancer metastasis, 
angiogenesis, cell migration
and wound healing.
Three different DNAzymes
(Dz372, Dz483, Dz720) targeted
against three separate purine and
pyrimidine junction in uPAR mRNA.
Discussion (DDS)(8)
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Stability of DNAzymes
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 pH values from 5 to 7(2)
 relative humidity (RH) (2)
 Preservatives(2)
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Dnaese 1
Benzoic acid
Degrraditin
DNAzyme
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DNAzyme recovery (%)
Samples 0.5 h 1.0 h 2.0 h
Aqueous solut. 44 22 7
Acetate buffer 57 30 6
SME 25 10 2
Protective DDS 101 84 70
Dermatitis(Dz13)
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 Characteristic(Dz13)
 10–23 DNAzymes(2)
 Hydrophilic(2)
 high molecular weight (MW) (2)
 negative charge(2)
Dermatitis(Dz13)
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Lipid 
barrier
Skin is 
enzymaticall
activity
Physiological 
barriers
Applications the Dz13
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 protein c-Jun(2)
 suppressing the growth of squamous and basal cell(2)
Conclusion
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 easy to synthesize and functionalize(9)
 multiple enzymatic turnover properties(6)
 high loading efficiency of nanomaterials(4)
Conclusion
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 cleave an all-RNA(2)
 mRNA-targeted gene silencing(3)
 gene therapeutic(1)
Conclusion
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 hairpins or aptamer–DNAzyme conjugates
 anticipated to appear on the market in the near future
 basic research level
Software
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